Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- UPDATE
July 5, 2004
- PFSB Specifies Measures to Prevent Medication Mistakes: Safety Info
July 5, 2004
- BULLETIN
July 5, 2004
- About 36% of the Population Has Allergic Symptoms: Korosho
July 5, 2004
- OTC NEWS IN BRIEF
July 5, 2004
- REGULATORY NEWS IN BRIEF
July 5, 2004
- DIAGNOSTICS NEWS IN BRIEF
July 5, 2004
- Pension Reform Bill Was the Main Achievement: Dr Sakaguchi
July 5, 2004
- MEDICAL DEVICE NEWS IN BRIEF
July 5, 2004
- Korosho to Draft GL for Life-sustaining Treatment in Terminal Care
July 5, 2004
- NEW PRODUCTS
July 5, 2004
- Sedative GL to Be Published in 2004: JSPM
July 5, 2004
- Meet the Leaders (34)
July 5, 2004
- NHO's Clinical Trial Network to Begin Large-scale Trials in 2004
July 5, 2004
- MPC Expanding Product Line in the Field of Cerebrovascular Disease
June 28, 2004
- MEDICAL DEVICE NEWS IN BRIEF
June 28, 2004
- BUSINESS NEWS IN BRIEF
June 28, 2004
- WORLDNEWS IN BRIEF
June 28, 2004
- Annual Business Results
June 28, 2004
- FPMAJ Report Outlines Future Issues in Regard to NHI Drug Pricing
June 28, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…